Want to see SE:HEART full AI Analyst Report?
HEART Stock Chart & Stats
kr25.80
kr0.30(2.04%)
At close: 4:00 PM EST
kr25.80
kr0.30(2.04%)
Day’s Range― - ―
52-Week Rangekr12.80 - kr29.89
Previous CloseN/A
Volume1.18K
Average Volume (3M)7.92K
Market Cap
kr190.35M
Enterprise Valuekr100.49M
Total Cash (Recent Filing)kr27.94M
Total Debt (Recent Filing)kr5.40M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.57
Shares Outstanding8,497,797
10 Day Avg. Volume3,221
30 Day Avg. Volume7,918
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr42.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Product FocusThe company is focused on a single, high-barrier product: the implantable Realheart TAH. A differentiated total artificial heart targets a structural, high-need market (advanced heart failure) where successful clinical and regulatory progress can create durable commercial barriers and specialized clinical adoption.
Modest LeverageReported debt remains low versus equity, giving the company more financial flexibility to fund ongoing R&D or bridge financing without heavy interest burden. Low leverage reduces bankruptcy risk and preserves capacity to raise capital on more favorable terms if clinical milestones progress.
Lean OrganizationA very small headcount implies low fixed overhead and focused resource allocation toward product development. For an R&D-stage medtech firm, lean operations can extend runway per funding round and concentrate expertise, supporting sustained development progress while limiting noncore cash burn.
Bears Say
Pre-revenue BusinessThe company remains effectively pre-revenue with negligible commercial sales history, meaning value depends entirely on future clinical/regulatory success and commercialization execution. This leaves long-term cash generation uncertain and increases reliance on external financing to reach market.
Persistent Cash BurnSustained negative operating and free cash flow indicate the business is not self-funding and continues to consume capital. Unless clinical or financing outcomes change, persistent cash burn will pressure liquidity and force dilutive financings, constraining the company’s ability to execute long-term plans.
Eroding Equity BaseThe declining equity base alongside repeated losses signals value dilution and deteriorating balance sheet resilience. Continued negative returns and shrinking shareholder equity limit cushion against setbacks, increasing the probability of future capital raises and ownership dilution for existing shareholders.
HEART FAQ
What was Scandinavian Real Heart AB’s price range in the past 12 months?
Scandinavian Real Heart AB lowest stock price was kr12.80 and its highest was kr29.89 in the past 12 months.
What is Scandinavian Real Heart AB’s market cap?
Scandinavian Real Heart AB’s market cap is kr190.35M.
When is Scandinavian Real Heart AB’s upcoming earnings report date?
Scandinavian Real Heart AB’s upcoming earnings report date is Aug 28, 2026 which is in 57 days.
How were Scandinavian Real Heart AB’s earnings last quarter?
Currently, no data Available
Is Scandinavian Real Heart AB overvalued?
According to Wall Street analysts Scandinavian Real Heart AB’s price is currently Overvalued.
Does Scandinavian Real Heart AB pay dividends?
Scandinavian Real Heart AB does not currently pay dividends.
What is Scandinavian Real Heart AB’s EPS estimate?
Scandinavian Real Heart AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scandinavian Real Heart AB have?
Scandinavian Real Heart AB has 8,497,797 shares outstanding.
What happened to Scandinavian Real Heart AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scandinavian Real Heart AB?
Currently, no hedge funds are holding shares in SE:HEART
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scandinavian Real Heart AB
Scandinavian Real Heart AB (Publ), a Swedish enterprise established in 2007, specializes in the innovation and production of artificial heart devices. The company's core focus is the Realheart TAH, a total artificial heart engineered specifically to address severe cases of heart failure. Beyond this central project, their product portfolio also encompasses medical solutions such as the RealVAD, PulsePump, and Sternal Prosthesis. The firm operates from its base in Västerås, Sweden.